White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
ROCKVILLE, Md., April 26, 2017 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2017 after 5:00 PM ET on Tuesday, May 9, 2017.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the first quarter 2017 results on Wednesday, May 10, 2017 at 9:00 AM ET. Following the presentation, the call will be open for questions.
A live webcast will be available on the supernus.com website, in the Investor section.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | ||||||||
| International dial-in: | (970) 315-0267 | ||||||||
| Conference ID: | 9981751 | ||||||||
| Conference Call Name: | Supernus Pharmaceuticals 1Q 2017 Earnings Conference Call | ||||||||
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for treatment of migraine and epilepsy and Oxtellar XR® (extended-release oxcarbazepine) for treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACTS: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
